Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Sponsor content
359 result(s) found, displaying 21 to 30
-
Jan-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WELIREG belzutifan 40 mg film-coated tablet blister pack.
-
Dec-2025Prescription medicine evaluationActive ingredient: Pneumococcal purified capsular polysaccharides.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine 0.5 mL Solution for Injection Pre-filled Syringe.
-
Australian Public Assessment Report (AusPAR)Capvaxive is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.
-
Australian Public Assessment Report (AusPAR)Winrevair (sotatercept) has been approved for the treatment of adults with pulmonary arterial hypertension (PAH) in WHO Functional Class (FC) II or III, in combination with standard therapy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Merck Sharp & Dohme (Australia) Pty Ltd - Prefilled syringe/needle.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WINREVAIR sotatercept 60 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WINREVAIR sotatercept 45 mg powder for injection vial.